Research programme: buprenorphine depot - Encore Therapeutics

Drug Profile

Research programme: buprenorphine depot - Encore Therapeutics

Alternative Names: ETI-311

Latest Information Update: 29 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Encore Therapeutics
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Opioid abuse; Pain

Most Recent Events

  • 26 Sep 2011 Research programme: buprenorphine depot is available for licensing worldwide as of 26 Sep 2011
  • 06 Apr 2011 Preclinical development is ongoing in USA
  • 09 Dec 2008 Preclinical trials in Opioid abuse in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top